Cumberland Picks Rolling NDA Path for Ifetroban in DMD Heart Disease
CPIX has more than doubled off its 52-week low of $1.85 on elevated volume (4.9× avg).
Summary
Cumberland will pursue a rolling NDA for ifetroban in Duchenne muscular dystrophy cardiomyopathy, filing sections with the FDA as they are completed rather than waiting for a single submission. It is going for Traditional Approval, not accelerated approval, and wants the Phase 2 FIGHT DMD trial plus natural history comparators accepted as pivotal evidence. That is the crux: the FDA previously suggested a Phase 3, so the agency's willingness to take Phase 2 data is the real gate here. The efficacy case rests on a Phase 2 left ventricular ejection fraction gain of 5.4% versus control (p=0.002), backed by a safety database of more than 1,400 subjects and orphan, rare pediatric and fast track designations. This comes after the August 28 8-K disclosing that long-term FIGHT DMD data would not be presented in August 2026 as previously expected, and follows the October 23 8-K on the ASSIST-SSc systemic sclerosis top-line. For a company that just sold its commercial portfolio for $100 million and is now essentially a pipeline story, the FDA's acceptance of the NDA and its agreement on the Phase 2-plus-registry package is the binary event.
At the time of this announcement, CPIX was trading at $5.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.2M. The 52-week trading range was $1.85 to $9.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.